Indications for treatment with nirsevimab beyond universal immunization of the newborn (replaces palivizumab indications).
- Inborn errors of metabolism.
- Neuromuscular disorders.
- Genetic syndromes with relevant respiratory problems.
- Down Syndrome.
- Those in “palliative care.”
Up to 24 months (2 vaccination campaigns).